Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53

Cancer Gene Therapy

Volumn 13, Issue 8, 2006, Pages 806-814

  Pataer, A ^a   Fanale, M A ^a   Roth, J A ^a   Swisher, S G ^a   Hunt, K K ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Amifostine (WR 2721); CDC2 protein kinase; Cyclin B1; Lung cancer; Olomoucine; p53

Indexed keywords

ADENOVIRUS VECTOR; AMIFOSTINE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; OLOMOUCINE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; AMIFOSTINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CDC2 PROTEIN KINASE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION; GENE THERAPY; GENES, BCL-2; GENES, P53; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS;

EID: 33746238959     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700960     Document Type: Article

References (39)

1. Thompson CB. Apoptosis in the pathogenesis, treatment of disease. Science 1995; 267: 1456-1462.
2. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-126.
3. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences, potential therapeutic applications. Cell Mol Life Sci 2004; 61: 2189-2199.
4. Cartron PF, Juin P, Oliver L, Meflah K, Valletta FM. Impact of proapoptotic proteins Bax and Bak in tumor progression and response to treatment. Expert Rev Anticancer Ther 2003; 3: 563-570.
5. Sharpless NE, DePinho RA. p53: good cop/bad cop. Cell 2002; 110: 9-12.
6. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
7. Swisher SG, Roth JA, Nemunaitis A, Lawrence DD, Kemp BL, Carrasco CH et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 763-771.
8. Ndoye A, Merlin JL, Leroux A, Dolivet G, Erbacher P, Behr JP et al. Enhanced gene transfer and cell death following p53 gene transfer using photochemical internalisation of glucosylated PEI-DNA complexes. J Gene Med 2004; 6: 884-894.
9. Wolf JK, Bodurka DC, Gano JB, Deavers M, Ramondetta L, Ramirez PT et al. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 2004; 94: 442-448.
10. Haupt S, Haupt Y. Improving cancer therapy through p53 management. Cell Cycle 2004; 3: 912-916.
11. Neyns B, Noppen M. Intratumoral gene therapy for non-small cell lung cancer: current status and future directions. Monaldi Arch Chest Dis 2003; 59: 287-295.
12. Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L et al. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996; 14: 1913-1921.
13. Glover D, Glick JH, Weiler C, Fox K, Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5: 574-578.
14. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985-991.
15. Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, Zou-Yang H et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 2002; 62: 2239-2243.
16. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979; 5: 85-91.
17. Pines J. Cell cycle and checkpoint on the nuclear frontier. Nature 1999; 397: 104-105.
18. Ribizzi I, Darnowski JW, Goulette FA, Sertoli MR, Calabresi P. Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line. Leuk Res 2000; 24: 519-525.
19. Giannopoulou E, Katsoris P, Kardamakis D, Papadimitriou E. Amifostine inhibits angiogenesis in vivo. J Pharmacol Exp Ther 2003; 304: 729-737.
20. Grdina DJ, Kataoka Y, Murley JS, Hunter N, Weichselbaum RR, Milas L. Inhibition of spontaneous metastases formation by amifostine. Int J Cancer 2002; 97: 135-141.
21. North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 2000; 19: 1206-1214.
22. Lee EJ, Gerhold M, Palmer MW, Christen RD. p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. Br J Cancer 2003; 88: 754-759.
23. Kataoka Y, Murley JS, Patel R, Grdina DJ. Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines. Int J Radiat Biol 2000; 76: 633-639.
24. Huang TS, Shu CH, Yang WK, Whang-Peng J. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Cancer Res 1997; 57: 2974-2978.
25. Shen SC, Huang TS, Jee SH, Luo ML. Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ 1998; 9: 23-29.
26. Martin SJ, McGahon AJ, Nisioka WK, LaFace D, Guo X, Th'ng J et al. p34cdc2 and apoptosis. Science 1995; 269: 106-107.
27. Hsu SL, Chen MC, Chou YH, Hwang GY, Yin SC. Induction of p21(CIP1/Waf1) and activation of p34(cdc2) involved in retinoic acid-induced apoptosis in human hepatoma Hep3B cells. Exp Cell Res 1999; 248: 87-96.
28. Liu HS, Chen CY, Lee CH, Chou YI. Selective activation of oncogenic Ha-ras-induced apoptosis in NIH/3T3 cells. Br J Cancer 1998; 77: 1777-1786.
29. Zaffaroni N, Silvestrini R, Orlandi L, Bearzatto A, Gornati D, Villa R. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br J Cancer 1998; 77: 1378-1385.
30. Kyprianou N, Bains A, Rhee JG. Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells. Prostate 1997; 32: 266-271.
31. Yao SL, Akhtar AJ, McKenna KA, Bedi GC, Sidransky D, Mabry M et al. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med 1996; 2: 1140-1143.
32. Cohen-Jonathan E, Toulas C, Monteil S, Couderc B, Maret A, Bard JJ et al. Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res 1997; 57: 1364-1370.
33. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH. Premature p34cdc2 activation required for apoptosis. Science 1994; 263: 1143-1145.
34. Furukawa Y, Iwase S, Terui Y, Kikuchi J, Sakai T, Nakamura M et al. Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells. J Biol Chem 1996; 271: 28469-28477.
35. Yao SL, McKenna KA, Sharkis SJ, Bedi A. Requirement of p34cdc2 kinase for apoptosis mediated by the Fas/APO-1 receptor and interleukin 1beta-converting enzyme-related proteases. Cancer Res 1996; 56: 4551-4555.
36. Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 1995; 55: 228-231.
37. Fotedar R, Flatt J, Gupta S, Margolis RL, Fitzgerald P, Messier H et al. Activation-induced T-cell death is cell cycle dependent and regulated by cyclin B. Mol Cell Biol 1995; 15: 932-942.
38. Ongkeko W, Ferguson DJ, Harris AL, Norbury C. Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J Cell Sci 1995; 108: 2897-2904.
39. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 1995; 86: 1148-1158.